JOSEPH FROEHNER: Open Payments
NPI 1811619307 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$601 in 30 payments from 11 companies in 2025. Trend: 2023 $155 · 2024 $106 · 2025 $601
Food & beverage: $601
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $187 |
| Novo Nordisk Inc | 4 | $84 |
| Lilly USA, LLC | 4 | $69 |
| Janssen Pharmaceuticals, Inc | 2 | $48 |
| HEARTFLOW, INC. | 1 | $47 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
Products named: VRAYLAR, Wegovy, SPRAVATO, FFRct, QULIPTA, REXULTI, MOUNJARO, JARDIANCE.
Industry payments across NE — which companies pay providers there.
